ArticleCancer discovery2019
Rational Targeting of Cooperating Layers of the Epigenome Yields Enhanced Therapeutic Efficacy against AML.
Open access · greenAbstract read
In one paragraph
Article in Cancer discovery, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.
0numbers the graph read from it
0cells of the map it votes in
29citing papers in PubMed
2.3field-weighted citation impact, top 11% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 46 citations in OpenAlex.
- MCL1 inhibition to enhance the efficacy of MYB targeting in pediatric acute myeloid leukemia.Cell death & disease · 2026Article
- Ficoll-based isolation biases the profiling of immune cells and leukemic blasts in AML samples.Frontiers in immunology · 2026Article
- Combinatorial inhibition of LSD1 and Menin induces therapeutic differentiation in AML.bioRxiv : the preprint server for biology · 2025Article
- Transcriptomic analysis of non-leukemic cell subsets in azacytidine-responsive AML highlights pathways associated with adhesion, platelet aggregation, and angiogenesis in mice and humans.Molecular medicine (Cambridge, Mass.) · 2025Article
- IRE1α-XBP1 safeguards hematopoietic stem and progenitor cells by restricting pro-leukemogenic gene programs.Nature immunology · 2025Article
- Super-enhancer DNA methylation in cancer: the mechanism of action and therapeutic directions.Frontiers in oncology · 2025Review
- Effects of Hypomethylating Agents on Gene Modulation in the Leukemic Microenvironment and Disease Trajectory in a Mouse Model of AML.bioRxiv : the preprint server for biology · 2024Article
- A gain-of-function p53 mutant synergizes with oncogenic NRAS to promote acute myeloid leukemia in mice.The Journal of clinical investigation · 2023Article
- The transcription factor HIF2α partakes in the differentiation block of acute myeloid leukemia.EMBO molecular medicine · 2023Article
- Article
- TET2 lesions enhance the aggressiveness of CEBPA-mutant acute myeloid leukemia by rebalancing GATA2 expression.Nature communications · 2023Article
- (R)-2-Hydroxyglutarate Inhibits KDM5 Histone Lysine Demethylases to Drive Transformation in IDH-Mutant Cancers.Cancer discovery · 2023Article
- High expression of LOC541471, GDAP1, SOD1, and STK25 is associated with poor overall survival of patients with acute myeloid leukemia.Cancer medicine · 2023Article
- Biallelic TET2 mutations confer sensitivity to 5'-azacitidine in acute myeloid leukemia.JCI insight · 2023Article
- One Omics Approach Does Not Rule Them All: The Metabolome and the Epigenome Join Forces in Haematological Malignancies.Epigenomes · 2021Review
- Hypomethylating Chemotherapeutic Agents as Therapy for Myelodysplastic Syndromes and Prevention of Acute Myeloid Leukemia.Pharmaceuticals (Basel, Switzerland) · 2021Review
- Combined epigenetic and metabolic treatments overcome differentiation blockade in acute myeloid leukemia.iScience · 2021Article
- Chemotherapy Induces Senescence-Like Resilient Cells Capable of Initiating AML Recurrence.Cancer discovery · 2021Article
- Superior efficacy of co-targeting GFI1/KDM1A and BRD4 against AML and post-MPN secondary AML cells.Blood cancer journal · 2021Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
23 authors at 6 institutions in 1 country.
Cihangir DuyDepartment of Medicine, Division of Hematology and Medical Oncology, Weill Cornell Medicine, New York, New York. amm2014@med.cornell.edu carroll2@pennmedicine.upenn.edu cid2001@med.cornell.edu.
Matt TeaterDepartment of Medicine, Division of Hematology and Medical Oncology, Weill Cornell Medicine, New York, New York.ORCID 0000-0001-9415-1659
Francine E Garrett-BakelmanDepartment of Medicine, Division of Hematology and Medical Oncology, Weill Cornell Medicine, New York, New York.
Tak C LeeDepartment of Medicine, Division of Hematology and Medical Oncology, Weill Cornell Medicine, New York, New York.
Cem MeydanInstitute for Computational Biomedicine and Department of Physiology and Biophysics, Weill Cornell Medical College, New York, New York.ORCID 0000-0002-0663-6216
Jacob L GlassMemorial Sloan Kettering Cancer Center, New York, New York.
Meng LiDepartment of Medicine, Division of Hematology and Medical Oncology, Weill Cornell Medicine, New York, New York.
Johannes C HellmuthDepartment of Medicine, Division of Hematology and Medical Oncology, Weill Cornell Medicine, New York, New York.ORCID 0000-0001-8409-3037
Helai P MohammadGlaxoSmithKline, Collegeville, Pennsylvania.
Kimberly N SmithemanGlaxoSmithKline, Collegeville, Pennsylvania.
Alan H ShihMemorial Sloan Kettering Cancer Center, New York, New York.
Omar Abdel-WahabMemorial Sloan Kettering Cancer Center, New York, New York.
Martin S TallmanMemorial Sloan Kettering Cancer Center, New York, New York.
Monica L GuzmanDepartment of Medicine, Division of Hematology and Medical Oncology, Weill Cornell Medicine, New York, New York.
David MuenchDivision of Immunobiology, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio.ORCID 0000-0002-8723-3389
H Leighton GrimesDivision of Immunobiology, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio.ORCID 0000-0001-8162-6758
Gail J RobozDepartment of Medicine, Division of Hematology and Medical Oncology, Weill Cornell Medicine, New York, New York.
Ryan G KrugerGlaxoSmithKline, Collegeville, Pennsylvania.
Caretha L CreasyGlaxoSmithKline, Collegeville, Pennsylvania.
Elisabeth M PaiettaOncology, Montefiore Medical Center, Bronx, New York.
Ross L LevineMemorial Sloan Kettering Cancer Center, New York, New York.
Martin CarrollDivision of Hematology and Oncology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania. amm2014@med.cornell.edu carroll2@pennmedicine.upenn.edu cid2001@med.cornell.edu.
Ari M MelnickDepartment of Medicine, Division of Hematology and Medical Oncology, Weill Cornell Medicine, New York, New York. amm2014@med.cornell.edu carroll2@pennmedicine.upenn.edu cid2001@med.cornell.edu.
Cornell University · USMemorial Sloan Kettering Cancer Center · USGlaxoSmithKline (United States) · USCincinnati Children's Hospital Medical Center · USMontefiore Medical Center · USUniversity of Pennsylvania · US
Funding
X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Elisa de Stanchina · 1985 to 2026
$347.4MProject-006U10CA180820 · NCI · ECOG-ACRIN MEDICAL RESEARCH FOUNDATION · PI Peter J ODwyer, MITCHELL D. SCHNALL · 2014 to 2026
$167.6MECOG-ACRIN Biospecimen Bank to Support NCTNU24CA196172 · NCI · ECOG-ACRIN MEDICAL RESEARCH FOUNDATION · PI STANLEY R. HAMILTON, Scott D Jewell · 2015 to 2026
$41.1MNetwork Lead Academic Participating Site: Memorial Sloan Kettering Cancer CenterUG1CA233290 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI CAROL AGHAJANIAN, Darren Feldman · 2019 to 2026
$10.2MTargeting Epigenetic Circuits in B-Cell LymphomasR35CA220499 · NCI · WEILL MEDICAL COLL OF CORNELL UNIV · PI MELNICK, ARI M. · 2018 to 2024
$7.2MECOG-ACRIN Integrated Leukemia Translational Science Center (LTSC)UG1CA233332 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI CAI, SHENG, LEVINE, ROSS L · 2019 to 2025
$6.2MUnderstanding and Targeting Chemotherapy Resistance in Acute Myeloid LeukemiaR01CA198089 · NCI · UNIVERSITY OF PENNSYLVANIA · PI CARROLL, MARTIN · 2015 to 2019
$3.3MECOG-ACRIN INTEGRATED LEUKEMIA TRANSLATIONAL RESEARCH CENTERU10CA180827 · NCI · MONTEFIORE MEDICAL CENTER (BRONX, NY) · PI LEVINE, ROSS L, MELNICK, ARI M. · 2014 to 2018
$3.0MGenetic and epigenetic basis of relapse in acute myeloid leukemiaK08CA169055 · NCI · WEILL MEDICAL COLL OF CORNELL UNIV · PI GARRETT-BAKELMAN, FRANCINE EVALINA · 2012 to 2016
$742kNCI NIH HHS K08 CA169055NCI NIH HHS P30 CA008748NCI NIH HHS R01 CA198089NCI NIH HHS R35 CA220499NCI NIH HHS U10 CA180820NCI NIH HHS U10 CA180827NCI NIH HHS U24 CA196172NCI NIH HHS UG1 CA233290NCI NIH HHS UG1 CA233332
Abstract
Disruption of epigenetic regulation is a hallmark of acute myeloid leukemia (AML), but epigenetic therapy is complicated by the complexity of the epigenome. Herein, we developed a long-term primary AML
Indexed as
AnimalsAntineoplastic Combined Chemotherapy ProtocolsAzacitidineDioxygenasesDNA-Binding ProteinsDNA (Cytosine-5-)-Methyltransferase 1DNA MethylationEnhancer Elements, GeneticEpigenomeGATA2 Transcription FactorGenes, Tumor SuppressorHistone DemethylasesHumansLeukemia, Myeloid, AcuteMiceMice, Inbred NODAzacitidineDioxygenasesDNA-Binding ProteinsDNA (Cytosine-5-)-Methyltransferase 1DNMT1 protein, humanGATA2 protein, humanGATA2 Transcription FactorHistone DemethylasesKDM1A protein, humanProto-Oncogene ProteinsTET2 protein, human
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.